INS and type 2 diabetes mellitus: Prior research in type 2 diabetes has consistently demonstrated the potent glycemic control offered by insulin and the cardiovascular and renal benefits associated with SGLT2i, which is reflected in our results specific to the PTDM population (21, 22).